Literature DB >> 26796540

Deficits in GABAA receptor function and working memory in non-smokers with schizophrenia.

Alanna C Bridgman1, Mera S Barr2, Michelle S Goodman1, Robert Chen3, Tarek K Rajji4, Zafiris J Daskalakis5, Tony P George6.   

Abstract

BACKGROUND: Although altered gamma-aminobutyric acid (GABA) neurotransmission has been implicated in the pathophysiology of schizophrenia, it is unclear whether the influence of GABA on working memory processes is confounded by nicotine use in this population. It is therefore crucial to evaluate working memory and its underlying mechanisms in non-smokers with schizophrenia to eliminate the confounding effects of nicotine on behavior and neurophysiology.
METHODS: In this cross-sectional study, working memory was assessed using the verbal N-back task, while GABAergic function was assessed through motor cortical inhibition using single and paired-pulse transcranial magnetic stimulation (TMS) to the left primary motor cortex in 11 non-smokers with schizophrenia and 13 non-smoker healthy subjects.
RESULTS: Similar to previously published studies, working memory performance was significantly impaired in the 3-back condition in patients with schizophrenia compared to healthy subjects (p=0.036). In addition, GABAA receptor function was significantly reduced in schizophrenia as assessed by short interval cortical inhibition (SICI) (p=0.005). A positive correlation was found between GABAA inhibition and working memory performance on the 3-back task (r(23)=0.55, p=0.006), suggesting that greater GABAA inhibition is associated with better performance on tasks of working memory.
CONCLUSIONS: Our findings highlight the role of GABAA receptor dysfunction in working memory and the pathophysiology of schizophrenia, and may represent a selective characteristic of schizophrenia. Moreover, these findings suggest a potential therapeutic role for targeting GABA receptor activity to improve cognition and quality of life in patients with schizophrenia.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cortical inhibition; Gamma-aminobutyric acid; N-back task; Transcranial magnetic stimulation

Mesh:

Substances:

Year:  2016        PMID: 26796540     DOI: 10.1016/j.schres.2016.01.008

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  6 in total

1.  Altered Motor-Striatal Plasticity and Cortical Functioning in Patients with Schizophrenia.

Authors:  Dongsheng Zhou; Feng Pang; Shiyan Liu; Ying Shen; Lingjiang Liu; Zezhong Fang; Chuang Wang; Zhenyu Hu; Ti-Fei Yuan
Journal:  Neurosci Bull       Date:  2016-11-12       Impact factor: 5.203

2.  A systematic review of TMS and neurophysiological biometrics in patients with schizophrenia.

Authors:  Meng di Hou; Viviana Santoro; Andrea Biondi; Sukhi S Shergill; Isabella Premoli
Journal:  J Psychiatry Neurosci       Date:  2021-12-21       Impact factor: 6.186

Review 3.  Have Standard Tests of Cognitive Function Been Misappropriated in the Study of Cognitive Enhancement?

Authors:  Iseult A Cremen; Richard G Carson
Journal:  Front Hum Neurosci       Date:  2017-05-24       Impact factor: 3.169

4.  Single-Pulse Transcranial Magnetic Stimulation-Evoked Potential Amplitudes and Latencies in the Motor and Dorsolateral Prefrontal Cortex among Young, Older Healthy Participants, and Schizophrenia Patients.

Authors:  Yoshihiro Noda; Mera S Barr; Reza Zomorrodi; Robin F H Cash; Pantelis Lioumis; Robert Chen; Zafiris J Daskalakis; Daniel M Blumberger
Journal:  J Pers Med       Date:  2021-01-17

5.  Evaluation of short interval cortical inhibition and intracortical facilitation from the dorsolateral prefrontal cortex in patients with schizophrenia.

Authors:  Yoshihiro Noda; Mera S Barr; Reza Zomorrodi; Robin F H Cash; Faranak Farzan; Tarek K Rajji; Robert Chen; Zafiris J Daskalakis; Daniel M Blumberger
Journal:  Sci Rep       Date:  2017-12-06       Impact factor: 4.379

Review 6.  Understanding Cortical Dysfunction in Schizophrenia With TMS/EEG.

Authors:  Aadith Vittala; Nicholas Murphy; Atul Maheshwari; Vaishnav Krishnan
Journal:  Front Neurosci       Date:  2020-05-28       Impact factor: 4.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.